Impact of Insurance Coverage on the Use an Effects of Smoking Cessation Medications
Tóm tắt
Tobacco use is not only the chief preventable cause of death, but it is also a very important contributor to the cause or complications of most chronic diseases. Therefore, facilitating smoking cessation should be very important to more effective disease management. Well-accepted, evidence-based guidelines describe effective clinical actions in support of smoking cessation; however, they are not followed as well as desired. This article focuses on the question of whether health insurance coverage for cessation medications (one of the effective actions) is important for their use and effectiveness. Although there have been accelerating calls from advocates for this coverage and a parallel increase in health plans and government programs providing such coverage, the evidence base is both recent and limited. Three major studies now suggest that coverage or cost sharing may only be effective when combined with extraordinary efforts to ensure that smokers are aware of the benefit and can access it easily. However, it is unclear whether many payors are willing to do that. Chronic disease management programs should definitely be focusing on whatever they can do to encourage smoking cessation. There is good evidence that repeated advice and support (and pharmacotherapy) from a variety of healthcare professionals is effective, especially when it is combined with the other care that patients receive. Since few other patient behaviors contribute as much to the causes and complications of most chronic diseases, great emphasis should be placed on changing this one.
Tài liệu tham khảo
Centers for Disease Control. Annual smoking-attributable mortality, years of potential life lost, and economic costs: United States, 1995–1999. MMWR Morb Mortal Wkly Rep 2002; 51: 300–3
McGinnis JM, Foege WH. Actual causes of death in the United States. JAMA 1993 Nov 10; 270(18): 2207–12
Nusselder WJ, Looman CWN, Marang-van de Mheen PJ, et al. Smoking and the compression of morbidity. J Epidemiol Community Health 2000 Aug; 54(8): 566–74
US Department of Health and Human Services. The health benefits of smoking cessation: a report of the Surgeon General. Washington (DC): US Government Printing Office, 1990. DHHS publication no.: 90–8416
Canadian Task Force on the Periodic Health Examination. The Canadian Guide to Clinical Preventive Health Care. Ottawa: The Minister of Supply and Services Canada, 1994
US Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore (MD): Williams & Wilkins, 1996
Raw M, Anderson P, Batra A, et al. World Health Organization European Partnership Project to Reduce Tobacco Dependence. WHO Europe evidence based recommendations on the treatment of tobacco dependence. Tob Control 2002 Mar; 11(1): 44–6
Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence: a clinical practice guideline. Rockville (MD): US Department of Health and Human Services, 2000. AHRQ publication no. 00-0032
Task Force on Community Preventive Services. Recommendations regarding interventions to reduce tobacco use and exposure to environmental tobacco smoke. Am J Prev Med 2001; 20 (2 Suppl.): 10–5
Hopkins DP, Briss PA, Ricard CJ, et al. Task Force on Community Preventive Services. Reviews of evidence regarding intervention to reduce tobacco use and exposure to environmental tobacco smoke. Am J Prev Med 2001 Feb; 20 (2 Suppl.): 16–66
Anda RF, Remington PL, Sienko DG, et al. Are physicians advising smokers to quit? The patient’s perspective. JAMA 1987 Apr 10; 257(14): 1916–9
Thorndike AN, Rigotti NA, Stafford RS, et al. National patterns in the treatment of smokers by physicians. JAMA 1998 Feb 25; 279(8): 604–8
Malarcher AM, Ford ES, Nelson DE, et al. Trends in cigarette smoking and physicians’ advice to quit smoking among people with diabetes in the US. Diabetes Care 1995 May; 18(5): 694–7
Doescher MP, Saver BG. Physicians’ advice to quit smoking: the glass remains half empty. J Fam Pract 2000 Jun; 49(6): 543–7
McIlvain HE, Crabtree BF, Backer EL, et al. Use of office-based smoking cessation activities in family practices. J Fam Pract 2000 Nov; 49(11): 1025–9
Ellerbeck EF, Ahluwalia JS, Jolicoeur DG, et al. Direct observation of smoking cessation activities in primary care practice. J Fam Pract 2001 Aug; 50(8): 688–93
Joseph AM, Arikian NJ, An LC, et al. Results of a randomized controlled trial of intervention to implement smoking guidelines in Veterans Affairs medical centers: increased use of medications without cessation benefit. Med Care 2004; 42(11): 1100–10
Manley MW, Griffin T, Foldes SS, et al. The role of health plans in tobacco control. Annu Rev Public Health 2003; 24: 247–66
Warner KE. Interpretation of the evidence and implications for coverage: cost effectiveness of smoking-cessation therapies. Pharmacoeconomics 1997 Jun; 11(6): 538–49
Schauffler HH, Parkinson MD. Health insurance coverage for smoking cessation services. Health Educ Q 1993 Summer; 20(2): 185–206
US Department of Health and Human Services. The health consequences of smoking — nicotine addiction: a report of the Surgeon General. Washington (DC): US Government Printing Office, 1988
US Preventive Services Task Force. Guide to clinical preventive services: an assessment of the effectiveness of 169 interventions. Baltimore (MD): Williams & Wilkins, 1989
US Department of Health and Human Services. Healthy people 2000: National health promotion and disease prevention objectives. Washington (DC): US Government Printing Office. DHHS publication no.: 91-50212
McPhillips-Tangum C. Results from the first annual survey on addressing tobacco in managed care. Tob Control 1998 Winter; (7 Suppl.): S11–3
Halpin HH, Ibrahim J, Husten CG. State Medicaid coverage for tobacco-dependence treatments: United States, 1994–2001. MMWR Morb Mortal Wkly Rep 2003 May 30; 52(21): 496–500
McPhillips-Tangum C, Cahill A, Bocchino C, et al. Addressing tobacco in managed care: results of the 2000 survey. Prev Med Managed Care 2002; 3(3): 85–94
Schauffler HH, Barker D. State Medicaid coverage for tobacco-dependence treatments: United States, 1998 and 2000. MMWR Morb Mortal Wkly Rep 2001 Nov 9; 50(44): 979–82
Schauffler HH, Barker DC, Orleans CT. Medicaid coverage for tobacco-dependence treatments. Health Aff 2001 Jan-Feb; 20(1): 298–303
Halpin HA, McMenamin SB, Keeler CL, et al. State Medicaid coverage for tobacco-dependence treatments: United States, 1994–2002. MMWR Morb Mortal Wkly Rep 2004; 53(3): 54–7
Newhouse JP, Manning W, Morris C, et al. Some interim results from a controlled trial of cost sharing in health insurance. N Engl J Med 1981 Dec 17; 305(25): 1501–7
Lohr KN, Brook RH, Kamberg CJ, et al. Use of medical care in the Rand Health Insurance Experiment: diagnosis- and service-specific analyses in a randomized controlled trial. Med Care 1986 Sep; 24 (9 Suppl.): S1–87
Cherkin DC, Grothaus L, Wagner EH. The effect of office visit copayments on preventive care services in an HMO. Inquiry 1990 Spring; 27(1): 24–38
Woolhandler S, Himmelstein DU. Reverse targeting of preventive care due to lack of health insurance. JAMA 1988 May 20; 259(19): 2872–4
Faulkner LA, Schauffler HH. The effect of health insurance coverage on the appropriate use of recommended clinical preventive services. Am J Prev Med 1997 Nov–Dec; 13(6): 453–8
Solanki G, Schauffler HH. Cost-sharing and the utilization of clinical preventive services. Am J Prev Med 1999; 17(2): 127–33
Solberg LI, Brekke ML, Kottke TE. Are physicians less likely to recommend preventive services to low-SES patients? Prev Med 1997 May–Jun; 26(3): 350–7
Curry SJ, Grouthaus MA, McAfee T, et al. Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization. N Engl J Med 1998 Sep; 339(10): 673–9
Schauffler HH, McMenamin S, Olson K, et al. Variations in treatment benefits influence smoking cessation: results of a randomised controlled trial. Tob Control 2001 Jun; 10(2): 175–80
Boyle RG, Magnan S, Solberg LI, et al. Does insurance coverage for drug therapy affect smoking cessation? Health Aff 2002 Nov–Dec; 21(6): 162–8
Cox JL, McKenna JP. Nicotine gum: does providing it free in a smoking cessation program alter success rates? J Fam Pract 1990 Sep; 31(3): 278–80
Hughes JR, Wadland WC, Fenwick JW, et al. Effect of cost on the self-administration and efficacy of nicotine gum: a preliminary study. Prev Med 1991; 20: 486–96
Sidorov J, Christianson M, Girolami S, et al. A successful tobacco cessation program led by primary care nurses in a managed care setting. Am J Manag Care 1997 Feb; 3(2): 207–14
Jaen CR, Cummings KM, Shah D, et al. Patterns of use of a free nicotine patch program for Medicaid and uninsured patients. J Natl Med Assoc 1997 May; 89(5): 325–8
Burns ME, Fiore MC. Under-use of tobacco dependence treatment among Wisconsin’s fee-for-service Medicaid recipients. WMJ 2001; 100(3): 54–8
Doescher MP, Whinston MA, Goo A, et al. Pilot study of enhanced tobacco-cessation services coverage for low-income smokers. Nicotine Tob Res 2002; 4 (1 Suppl.): S19–24
Lichtenstein E, Hollis JF. Patient referral to a smoking cessation program: who follows through? J Fam Pract 1992; 34(6): 739–44
Alesci NL, Boyle RG, Davidson G, et al. Does a health plan effort to increase smokers’ awareness of cessation medication coverage increase utilization and cessation? Am J Health Promot 2004; 18(5): 366–9
Schauffler HH. Defining benefits and payment for smoking cessation treatments. Tob Control 1997; 6 (1 Suppl.): S81–5
Chang CF. A critical review of the arguments for insurance coverage for smoking-cessation therapies. Manag Care 2001 May; 10(5): 62–5